A detailed history of Macquarie Group LTD transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Macquarie Group LTD holds 774,613 shares of DVAX stock, worth $10 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
774,613
Previous 739,680 4.72%
Holding current value
$10 Million
Previous $8.31 Million 3.89%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.05 - $11.61 $351,076 - $405,572
34,933 Added 4.72%
774,613 $8.63 Million
Q2 2024

Aug 09, 2024

SELL
$10.73 - $12.58 $2,124 - $2,490
-198 Reduced 0.03%
739,680 $8.31 Million
Q1 2024

May 14, 2024

SELL
$11.7 - $14.98 $487,691 - $624,411
-41,683 Reduced 5.33%
739,878 $9.18 Million
Q4 2023

Feb 14, 2024

SELL
$13.09 - $14.98 $1.65 Million - $1.89 Million
-126,143 Reduced 13.9%
781,561 $10.9 Million
Q3 2023

Nov 14, 2023

BUY
$12.64 - $14.99 $304,093 - $360,629
24,058 Added 2.72%
907,704 $13.4 Million
Q2 2023

Aug 14, 2023

BUY
$9.85 - $13.17 $1.22 Million - $1.63 Million
123,646 Added 16.27%
883,646 $11.4 Million
Q4 2022

Feb 21, 2023

SELL
$10.27 - $13.29 $10,331 - $13,369
-1,006 Reduced 0.13%
760,000 $8.09 Million
Q3 2022

Nov 14, 2022

SELL
$9.93 - $17.44 $18,310 - $32,159
-1,844 Reduced 0.24%
761,006 $7.96 Million
Q1 2021

May 14, 2021

SELL
$4.57 - $11.18 $3,994 - $9,771
-874 Reduced 0.11%
762,850 $7.5 Million
Q2 2020

Aug 11, 2020

BUY
$2.94 - $9.1 $10,948 - $33,888
3,724 Added 0.49%
763,724 $6.77 Million
Q1 2019

May 15, 2019

BUY
$7.08 - $12.09 $1.84 Million - $3.14 Million
260,000 Added 52.0%
760,000 $5.56 Million
Q4 2018

Feb 15, 2019

BUY
$8.14 - $13.28 $4.07 Million - $6.64 Million
500,000 New
500,000 $4.58 Million

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.64B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.